Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms
Neuroendocrine Neoplasm · Neuroendocrine Carcinomas · Neuroendocrine Tumors
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 58 (planned)
- Started
- Nov 2026
- Main results expected
- Sep 2028
- Fully finished
- Sep 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Evaluate the clinical activity of CTX-471
Measured over: Baseline until confirmed disease progression (up to 1 year)
Evaluate the safety of CTX-471
Measured over: From first dose of CTX-471 (Cycle 1 Day 1, Cycle = 2 weeks) until 30 days after the last dose of CTX-471
Determine the recommended phase 2 dose (RP2D) for CTX-471
Measured over: From first dose of CTX-471 (Cycle 1 Day 1, Cycle = 2 weeks) until 30 days after the last dose of CTX-471
Changes Tremor has spotted
Status changed: Not started yet → Signing up patients. Usually normal progress.
Spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- 2026-11-09 15:36 UTC · status_changed · overall_status
old: "NOT_YET_RECRUITING"
new: "RECRUITING"
Trial ID NCT07684170 · record last updated 2026-11-09 · checked 2026-11-09 15:36 UTC